Literature DB >> 25859122

Kenneth tanabe works to solve the mysteries of liver cancer: while progress has been relatively slow, this noted expert sees reasons for hope.

Jack McCain.   

Abstract

Dr. Tanabe, Chief of the Division of Surgical Oncology at Massachusetts General Hospital, studies preventing and treating hepatocellular carcinoma, the most rapidly rising cause of cancer-related mortality. Promising developments are on the horizon.

Entities:  

Year:  2015        PMID： 25859122      PMCID： PMC4378520     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  12 in total

1.  A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.

Authors:  Jiwei Huang; Lvnan Yan; Zheyu Cheng; Hong Wu; Liang Du; Jinzhou Wang; Yinglong Xu; Yong Zeng
Journal:  Ann Surg       Date:  2010-12       Impact factor: 12.969

Review 2.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

3.  A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Authors:  Barham K Abu Dayyeh; May Yang; Bryan C Fuchs; Daniel L Karl; Suguru Yamada; John J Sninsky; Thomas R O'Brien; Jules L Dienstag; Kenneth K Tanabe; Raymond T Chung
Journal:  Gastroenterology       Date:  2011-03-24       Impact factor: 22.682

4.  Molecular MRI of collagen to diagnose and stage liver fibrosis.

Authors:  Bryan C Fuchs; Huifang Wang; Yan Yang; Lan Wei; Miloslav Polasek; Daniel T Schühle; Gregory Y Lauwers; Ashfaq Parkar; Anthony J Sinskey; Kenneth K Tanabe; Peter Caravan
Journal:  J Hepatol       Date:  2013-07-06       Impact factor: 25.083

5.  Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.

Authors:  Bryan C Fuchs; Yujin Hoshida; Tsutomu Fujii; Lan Wei; Suguru Yamada; Gregory Y Lauwers; Christopher M McGinn; Danielle K DePeralta; Xintong Chen; Toshihiko Kuroda; Michael Lanuti; Anthony D Schmitt; Supriya Gupta; Andrew Crenshaw; Robert Onofrio; Bradley Taylor; Wendy Winckler; Nabeel Bardeesy; Peter Caravan; Todd R Golub; Kenneth K Tanabe
Journal:  Hepatology       Date:  2014-02-28       Impact factor: 17.425

6.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma.

Authors:  Kai Feng; Jun Yan; Xiaowu Li; Feng Xia; Kuansheng Ma; Shuguang Wang; Ping Bie; Jiahong Dong
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

7.  Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Kenneth K Tanabe; Antoinette Lemoine; Dianne M Finkelstein; Hiroshi Kawasaki; Tsutomu Fujii; Raymond T Chung; Gregory Y Lauwers; Yakup Kulu; Alona Muzikansky; Darshini Kuruppu; Michael Lanuti; Jonathan M Goodwin; Daniel Azoulay; Bryan C Fuchs
Journal:  JAMA       Date:  2008-01-02       Impact factor: 56.272

Review 8.  The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review.

Authors:  Zhi Ven Fong; Kenneth K Tanabe
Journal:  Cancer       Date:  2014-06-04       Impact factor: 6.860

Review 9.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

10.  Chronic hepatitis C virus (HCV) disease burden and cost in the United States.

Authors:  Homie Razavi; Antoine C Elkhoury; Elamin Elbasha; Chris Estes; Ken Pasini; Thierry Poynard; Ritesh Kumar
Journal:  Hepatology       Date:  2013-05-06       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.